168 related articles for article (PubMed ID: 35955694)
1. Reduced VDAC1, Maintained Mitochondrial Dynamics and Enhanced Mitochondrial Biogenesis in a Transgenic Tau Mouse Model of Alzheimer's Disease.
Vijayan M; Reddy PH
Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955694
[TBL] [Abstract][Full Text] [Related]
2. A partial reduction of VDAC1 enhances mitophagy, autophagy, synaptic activities in a transgenic Tau mouse model.
Vijayan M; Alvir RV; Alvir RV; Bunquin LE; Pradeepkiran JA; Reddy PH
Aging Cell; 2022 Aug; 21(8):e13663. PubMed ID: 35801276
[TBL] [Abstract][Full Text] [Related]
3. Abnormal interaction of VDAC1 with amyloid beta and phosphorylated tau causes mitochondrial dysfunction in Alzheimer's disease.
Manczak M; Reddy PH
Hum Mol Genet; 2012 Dec; 21(23):5131-46. PubMed ID: 22926141
[TBL] [Abstract][Full Text] [Related]
4. RNA silencing of genes involved in Alzheimer's disease enhances mitochondrial function and synaptic activity.
Manczak M; Reddy PH
Biochim Biophys Acta; 2013 Dec; 1832(12):2368-78. PubMed ID: 24063855
[TBL] [Abstract][Full Text] [Related]
5. Reduced dynamin-related protein 1 protects against phosphorylated Tau-induced mitochondrial dysfunction and synaptic damage in Alzheimer's disease.
Kandimalla R; Manczak M; Fry D; Suneetha Y; Sesaki H; Reddy PH
Hum Mol Genet; 2016 Nov; 25(22):4881-4897. PubMed ID: 28173111
[TBL] [Abstract][Full Text] [Related]
6. VDAC1, mitochondrial dysfunction, and Alzheimer's disease.
Shoshan-Barmatz V; Nahon-Crystal E; Shteinfer-Kuzmine A; Gupta R
Pharmacol Res; 2018 May; 131():87-101. PubMed ID: 29551631
[TBL] [Abstract][Full Text] [Related]
7. Is the mitochondrial outermembrane protein VDAC1 therapeutic target for Alzheimer's disease?
Reddy PH
Biochim Biophys Acta; 2013 Jan; 1832(1):67-75. PubMed ID: 22995655
[TBL] [Abstract][Full Text] [Related]
8. Reduced VDAC1 protects against Alzheimer's disease, mitochondria, and synaptic deficiencies.
Manczak M; Sheiko T; Craigen WJ; Reddy PH
J Alzheimers Dis; 2013; 37(4):679-90. PubMed ID: 23948905
[TBL] [Abstract][Full Text] [Related]
9. Enhanced expression of the voltage-dependent anion channel 1 (VDAC1) in Alzheimer's disease transgenic mice: an insight into the pathogenic effects of amyloid-β.
Cuadrado-Tejedor M; Vilariño M; Cabodevilla F; Del Río J; Frechilla D; Pérez-Mediavilla A
J Alzheimers Dis; 2011; 23(2):195-206. PubMed ID: 20930307
[TBL] [Abstract][Full Text] [Related]
10. A partial reduction of Drp1 improves cognitive behavior and enhances mitophagy, autophagy and dendritic spines in a transgenic Tau mouse model of Alzheimer disease.
Kandimalla R; Manczak M; Pradeepkiran JA; Morton H; Reddy PH
Hum Mol Genet; 2022 Jun; 31(11):1788-1805. PubMed ID: 34919689
[TBL] [Abstract][Full Text] [Related]
11. Hippocampal phosphorylated tau induced cognitive decline, dendritic spine loss and mitochondrial abnormalities in a mouse model of Alzheimer's disease.
Kandimalla R; Manczak M; Yin X; Wang R; Reddy PH
Hum Mol Genet; 2018 Jan; 27(1):30-40. PubMed ID: 29040533
[TBL] [Abstract][Full Text] [Related]
12. Targeting the overexpressed mitochondrial protein VDAC1 in a mouse model of Alzheimer's disease protects against mitochondrial dysfunction and mitigates brain pathology.
Verma A; Shteinfer-Kuzmine A; Kamenetsky N; Pittala S; Paul A; Nahon Crystal E; Ouro A; Chalifa-Caspi V; Pandey SK; Monsonego A; Vardi N; Knafo S; Shoshan-Barmatz V
Transl Neurodegener; 2022 Dec; 11(1):58. PubMed ID: 36578022
[TBL] [Abstract][Full Text] [Related]
13. The Voltage-dependent Anion Channel 1 Mediates Amyloid β Toxicity and Represents a Potential Target for Alzheimer Disease Therapy.
Smilansky A; Dangoor L; Nakdimon I; Ben-Hail D; Mizrachi D; Shoshan-Barmatz V
J Biol Chem; 2015 Dec; 290(52):30670-83. PubMed ID: 26542804
[TBL] [Abstract][Full Text] [Related]
14. Protective effects of a small-molecule inhibitor DDQ against tau-induced toxicities in a transgenic tau mouse model of Alzheimer's disease.
Vijayan M; George M; Bunquin LE; Bose C; Reddy PH
Hum Mol Genet; 2022 Mar; 31(7):1022-1034. PubMed ID: 34559191
[TBL] [Abstract][Full Text] [Related]
15. Abnormal interaction between the mitochondrial fission protein Drp1 and hyperphosphorylated tau in Alzheimer's disease neurons: implications for mitochondrial dysfunction and neuronal damage.
Manczak M; Reddy PH
Hum Mol Genet; 2012 Jun; 21(11):2538-47. PubMed ID: 22367970
[TBL] [Abstract][Full Text] [Related]
16. Mitophagy enhancers against phosphorylated Tau-induced mitochondrial and synaptic toxicities in Alzheimer disease.
Kshirsagar S; Sawant N; Morton H; Reddy AP; Reddy PH
Pharmacol Res; 2021 Dec; 174():105973. PubMed ID: 34763094
[TBL] [Abstract][Full Text] [Related]
17. Protective effects of reduced dynamin-related protein 1 against amyloid beta-induced mitochondrial dysfunction and synaptic damage in Alzheimer's disease.
Manczak M; Kandimalla R; Fry D; Sesaki H; Reddy PH
Hum Mol Genet; 2016 Dec; 25(23):5148-5166. PubMed ID: 27677309
[TBL] [Abstract][Full Text] [Related]
18. Aβ promotes VDAC1 channel dephosphorylation in neuronal lipid rafts. Relevance to the mechanisms of neurotoxicity in Alzheimer's disease.
Fernandez-Echevarria C; Díaz M; Ferrer I; Canerina-Amaro A; Marin R
Neuroscience; 2014 Oct; 278():354-66. PubMed ID: 25168729
[TBL] [Abstract][Full Text] [Related]
19. Amyloid Beta and Phosphorylated Tau-Induced Defective Autophagy and Mitophagy in Alzheimer's Disease.
Reddy PH; Oliver DM
Cells; 2019 May; 8(5):. PubMed ID: 31121890
[TBL] [Abstract][Full Text] [Related]
20. Targeting the Mitochondrial Protein VDAC1 as a Potential Therapeutic Strategy in ALS.
Shteinfer-Kuzmine A; Argueti-Ostrovsky S; Leyton-Jaimes MF; Anand U; Abu-Hamad S; Zalk R; Shoshan-Barmatz V; Israelson A
Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
